For U.S. healthcare professionals only

test for kit d816v

Here you will find a range of useful resources to support you in your understanding of systemic mastocytosis (SM), including links to associated organizations and advocacy groups.

Find a lab

High-sensitivity KIT D816V testing is available through the independent labs listed below:
ARUP Laboratories
Mayo Clinic Laboratories
Versiti
Blueprint Medicines is not affiliated with these organizations, and does not endorse any particular test, service, or laboratory. Blueprint Medicines is not responsible for the content of these websites and makes no guarantee about the accuracy of the information or the quality of services provided. This list is provided as a convenience only and may not be exhaustive. Blueprint Medicines may update the list from time to time as it becomes aware of other commercial laboratories offering high-sensitivity KIT D816V assays.

Resources for clinicians

SM-LeaveBehind-Allergist-Immunologists_thumb

Allergist-Immunologist Quick Guide to KIT D816V in SM

SM-LeaveBehind-Hemoncs_thumb

Hematologist-Oncologist Quick Guide to KIT D816V in SM

Additional resources

Global Genes

National Organization for Rare Disorders

The Mast Cell Disease Society

TargetSM

A resource on systemic mastocytosis from the perspectives of experts in oncology, hematology, allergy and immunology, and pathology—managed by Blueprint Medicines.

Independent advocacy groups are included as a resource only, and do not imply endorsement of the company or its products by the groups listed. Blueprint Medicines is not affiliated with and does not endorse any particular advocacy group. We make no guarantees about the accuracy of the information provided on advocacy groups’ websites or the quality of support provided.

Get information and updates delivered to your inbox.

SIGN UP
  1. Garcia-Montero AC, et al. Blood. 2006;108(7):2366-2372.
  2. Verstovsek S. Eur J Haematol. 2013;90(2):89-98.
  3. Gilreath JA, et al. Clin Pharmacol. 2019;11:77-92.
  4. Metcalfe DD. Blood. 2008;112(4):946-956.
  5. Theoharides TC, et al. N Engl J Med. 2015;373(2):163-172.
  6. Hartmann K, et al. J Allergy Clin Immunol. 2016;137(1):35-45.
  7. Shomali W, Gotlib J. Hematology Am Soc Hematol Educ Program. 2018(1):127-136.
  8. Lim KH, et al. Blood. 2009;113(23):5727-5736.
  9. Kibsgaard L, et al. Derm. 2020;6:294-300.
  10. Sperr WR, et al. Lancet Haematol. 2019;6(12):e638-e649.
  11. Trizuljak J, et al. Allergy. 2020;75(8):1927-1938.
  12. Arock M, et al. Leukemia. 2015;29(6):1223-1232.
  13. Hermine O, et al. PLoS One. 2008;3(5):e2266.
  14. Chatterjee A, et al. Oncotarget. 2015;6(21):18250-18264.
  15. Arber DA, et al. Blood. 2016;127(20):2391-2405.
  16. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev 4th ed. International Agency for Research on Cancer (IARC); 2017.
  17. da Silva EZ, et al. J Histochem Cytochem. 2014;62:698-738.
  18. Valent P, et al. Blood. 2017;129(11):1420-1427.
  19. Jennings SV, et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
  20. Amin K. Respir Med. 2012;106(1):9-14.
  21. Gulen T, et al. J Intern Med. 2016;279(3):211-228.
  22. Mickys U, et al. Dig Liver Dis. 2007;39(7):693-697.
  23. Akin C, Castells M; World Allergy Organization. July 2011. Updated March 2017. Accessed October 9, 2020.  https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/mastocytosis-where-are-we-now.
  24. Pardanani A, et al. Blood. 2010;115(1):150-151.
  25. Pardanani A. Am J Hematol. 2013;88(7):612-624.
  26. Data on file. Blueprint Medicines Corporation. Cambridge, MA. 2020.
  27. Kristensen T, et al. Am J Hematol. 2014;89(5):493-498.
  28. van Anrooij B, et al. Allergy. 2016;71(11):1585-1593.
  29. Vos B, et al. J Allergy Clin Immunol Pract. 2017;5(5):1264-1271.
  30. Berezowska S, et al. Mod Pathol. 2014;27(1):19-29.
  31. Gulen T, et al. J Allergy Clin Immunol Pract. 2017;5:1248-1255.
  32. Hahn HP, Hornick JL. Am J Surg Pathol. 2007;31(11):1669-1676.
  33. Craig JW, et al. Mod Pathol. 2020;133(6):1135-1145.
  34. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Systemic Mastocytosis V.1.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  35. Pardanani A. Am J Hematol. 2019;94(3):363-377.
  36. Akin C, Valent P. Immunol Allergy Clin North Am. 2014;34(2):207-218.
  37. Valent P, et al. Int J Mol Sci. 2019;20(12):2976.
  38. Akin C. J Mol Diagn. 2006;8(4):412-419.

This website is intended for U.S. healthcare professionals only. This website does not provide medical advice and is for educational purposes only.

Blueprint Medicines and associated logo are trademarks of Blueprint Medicines Corporation.

All other trademarks are the property of their respective owners.

© 2021 Blueprint Medicines Corporation.

04/2021     USBP-PRSM-20.011.3

UncoverKIT and the information contained in this site are intended for U.S. healthcare professionals only.

By continuing, you confirm that you are a U.S. healthcare professional.

CONFIRM

You are about to leave UncoverKIT.com

You will enter a website that is not owned or controlled by Blueprint Medicines. Blueprint Medicines is not responsible for any information, statements, or other content you may encounter on third-party websites and makes no representation as to the accuracy of information contained on websites we do not own or control. Further, Blueprint Medicines does not recommend nor endorse the content of any third-party website. Your use of a third-party website is subject of the terms and conditions of use for such sites.

Go back